The FAME 2 (FFR-Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Therapy vs. Optimal Medical Therapy Alone in Patients with Stable Coronary Artery Disease) trial was conducted at 28 centres in Europe and North America to assess the role of FFR in the percutaneous treatment of stable coronary artery disease in one or more vessels.(1) Results were presented by the trial's co-ordinator Dr Bernard De Bruyne from the OLV Clinic in Aalst, Belgium. The study, which began in May 2010, enrolled 1220 patients with stable coronary artery disease, and compared clinical outcomes, safety and cost effectiveness of percutaneous coronary intervention (PCI) guided by FFR plus best available medical therapy (MT) with MT alone.
"These statistically significant results validate the important role that FFR-guided therapy has in improving outcomes for patients with coronary artery disease.
"The FAME 2 trial provides new evidence of the role that FFR and second-generation drug eluding stents can have in improving patient care. We now know that, if a lesion is significant as determined by FFR guidance, the stenting procedure will provide a better outcome. With this new knowledge, I believe that FFR should become the standard of care for treating most patients with stable coronary artery disease and significant coronary narrowings.”
Results showed that:
The FAME 2 trial was stopped early (January 2012) after its independent data safety monitoring board (DSMB) deemed it unjustified to continue with the MT-alone arm. The DSMB found a statistically significant reduction in the need for unplanned hospital readmission and urgent revascularisation when FFR-guided assessment was used to direct treatment. As a result, patients already enrolled in the trial continued to be followed, but no new patients were added.
"The trial provides new information on the benefits of coronary intervention and answers questions raised by the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial, which found no difference in outcomes between PCI plus MT and MT alone," said Dr De Bruyne.
"The data show that in patients with stable CAD and functionally significant stenoses as assessed by FFR, FFR-guided PCI plus MT decreases the need for urgent revascularisation when compared with MT alone. In contrast, in patients without ischaemia-producing lesions, outcome is favourable with MT alone."
1. Fractional flow reserve specifically identifies which coronary narrowings are responsible for obstructing the blood flow (ischaemia) to a patient’s heart muscle.
About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 75,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2012
ESC Congress 2012 will take place from 25 to 29 August at the Messe München centre in Munich, Germany. Information on the scientific programme is available here. More information on ESC Congress 2012 is available from the ESC Press Office or contact us at email@example.com
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved